Brian Armstrong Backed Startup Raises $435M

$435M Series C Triples NewLimit's Valuation

NewLimit, the longevity biotech co-founded by Coinbase CEO Brian Armstrong (@brian_armstrong), has closed a $435 million Series C funding round. The raise values the company at $3.1 billion on a post-money basis. That is roughly triple its previous valuation, which sat below $1 billion as recently as its Series B last year.

The round was led by Founders Fund, alongside new investors Thrive Capital, Greenoaks, and Quiet Capital, and returning backers including Kleiner Perkins, Eli Lilly Ventures, and others. NewLimit was founded in 2021 by Armstrong, former GV partner and bioengineer Blake Byers, and Jacob Kimmel, a stem cell biologist.

This is the third time in the past year that the company has announced a fundraise, following a $130 million Series B in May 2025 and a further $45 million in October.

From Lab to Human Trials, Ahead of Schedule

NewLimit plans to bring its first aging reprogramming medicine to human clinical trials next year, with the accelerated timeline driven by the breakthrough discovery of a prototype medicine that reverses cell age in old human liver cells.

The liver reprogramming therapy is designed to allow livers to heal faster after injury, avoid damage from dietary challenges, and accelerate recovery from alcohol consumption. The initial phase 1 trial will focus on patients with fatty livers, with phase 2 development set to narrow in on alcohol-related liver disease.

NewLimit's medicines are designed to restore youthful function in old cells through epigenetic reprogramming, with emerging science demonstrating that aging is plastic at the cellular level. After closing its $130 million Series B with the expectation that it would take several years to develop a drug ready for clinical testing, NewLimit found that a promising compound emerged from its data far sooner than anticipated.

The funding comes amid growing investor interest in drugs designed to slow or reverse aging, with NewLimit joining several other tech billionaire-backed longevity startups in the space.

Sources:
NewLimit official blog: Series C announcement
STAT News: NewLimit raises $435 million ahead of first clinical trial
Fierce Biotech: NewLimit nabs $435M to rejuvenate old cells